MPR Weekly Dose Podcast #138

Newly approved gynecologic cancer treatment; Zejula use restricted; intrauterine system use extended; a second insulin product is approved as an interchangeable biosimilar to Lantus; and an FDA advisory committee takes a vote on tenapanor.